Roche Under Fire Over ‘Unaffordable’ COVID-19 Therapy Actemra
The WHO Calls For Lower Prices
The World Health Organization has taken the unusual step of calling for lower drug prices to help patient access IL-6 therapies in developing nations.
You may also be interested in...
In this week's podcast edition of Five Must-Know Things: Novartis’s US strategy for inclisiran; Roche under pressure over prices for Actemra in COVID; Lambda coronavirus variant poses new challenge for vaccines; GSK loses its oncology R&D head; and a look at expected Q3 approvals in the US.
The RECOVERY trial has found Actemra to help cut deaths and speed recovery – and UK doctors are not waiting for Roche to complete own studies.
The ex-chief medical officer at Novartis is now CEO at the UK-based biotech, which he he told Scrip could have a ‘transformational’ therapy to protect patients after a heart attack.